Mitsubishi UFJ Asset Management Co. Ltd. Increases Position in Cencora, Inc. $COR

Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in Cencora, Inc. (NYSE:COR) by 10.7% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 339,819 shares of the company’s stock after acquiring an additional 32,742 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Cencora were worth $101,895,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Atlantic Edge Private Wealth Management LLC grew its stake in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock valued at $25,000 after purchasing an additional 35 shares during the last quarter. Costello Asset Management INC purchased a new position in shares of Cencora in the first quarter worth about $28,000. University of Texas Texas AM Investment Management Co. acquired a new stake in shares of Cencora during the first quarter worth about $39,000. Hantz Financial Services Inc. lifted its holdings in shares of Cencora by 712.0% during the second quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after purchasing an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Cencora in the second quarter valued at approximately $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Cencora Trading Up 0.1%

Shares of COR stock opened at $360.56 on Friday. The company has a debt-to-equity ratio of 3.64, a current ratio of 0.90 and a quick ratio of 0.53. The company has a market cap of $69.90 billion, a price-to-earnings ratio of 37.09, a PEG ratio of 1.56 and a beta of 0.63. The stock has a 50 day simple moving average of $314.27 and a 200-day simple moving average of $299.44. Cencora, Inc. has a 1-year low of $223.92 and a 1-year high of $364.36.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.79 by $0.05. The firm had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same quarter last year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be given a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date is Friday, November 14th. Cencora’s dividend payout ratio (DPR) is 30.19%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on COR shares. UBS Group increased their price objective on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday. Wall Street Zen upgraded Cencora from a “hold” rating to a “buy” rating in a research note on Saturday. Robert W. Baird boosted their price objective on Cencora from $355.00 to $395.00 and gave the company an “outperform” rating in a report on Thursday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Morgan Stanley set a $330.00 price target on Cencora and gave the company an “equal weight” rating in a research report on Wednesday, July 16th. Eight equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $351.50.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the company’s stock in a transaction dated Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This represents a 9.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares in the company, valued at $12,398,792. This represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 41,544 shares of company stock valued at $12,230,941 in the last three months. Corporate insiders own 10.80% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.